BIGT:LSE:LSE-L&G Pharma Breakthrough UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 838.25

Change

-11.95 (-1.41)%

Market Cap

N/A

Volume

105.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+0.38 (+0.14%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.41 (+0.28%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.05 (+0.39%)

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.05 (+0.30%)

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.30 (-0.48%)

USD 266.08B
0QZO:LSE 0QZO

+8.80 (+8.82%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.08 (+0.26%)

USD 218.91B
0QZ3:LSE Qualcomm Inc.

+2.23 (+1.38%)

USD 202.26B

ETFs Containing BIGT:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.94% 33% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.94% 34% F 42% F
Trailing 12 Months  
Capital Gain 5.94% 34% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.94% 35% F 42% F
Trailing 5 Years  
Capital Gain 9.78% 38% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.78% 39% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain -1.71% 17% F 29% F
Dividend Return -1.71% 16% F 28% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.94% 62% D 78% C+
Risk Adjusted Return -15.61% 17% F 26% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.